Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/12/2005 11:14:18 AM
	of 3044

ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN - News) today reported interim results from two clinical trials of KOS-953, Kosan's proprietary formulation of the Hsp90 inhibitor 17-AAG, in two oral presentations at the 47th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA. Data from a Phase I single-agent clinical trial and a Phase Ib combination trial of KOS-953 co-administered with bortezomib (Velcade®) demonstrated early signs of anticancer activity and tolerability in patients with relapsed-refractory multiple myeloma. Message 21964985

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next